

# Jay A Berzofsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2558464/publications.pdf>

Version: 2024-02-01

239  
papers

20,129  
citations

9264

74  
h-index

11939

134  
g-index

241  
all docs

241  
docs citations

241  
times ranked

19598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. <i>Science</i> , 2018, 360, .	12.6	931
2	NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. <i>Nature Immunology</i> , 2000, 1, 515-520.	14.5	639
3	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. <i>Journal of Experimental Medicine</i> , 2005, 201, 139-148.	8.5	636
4	Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. <i>Journal of Molecular Biology</i> , 1987, 195, 659-685.	4.2	627
5	Transforming Growth Factor- $\beta$ Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte-mediated Tumor Immunosurveillance. <i>Journal of Experimental Medicine</i> , 2003, 198, 1741-1752.	8.5	508
6	Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. <i>Nature</i> , 1990, 344, 873-875.	27.8	505
7	Role of T-Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection. <i>Immunological Reviews</i> , 1992, 127, 183-204.	6.0	484
8	Commensal DNA Limits Regulatory T Cell Conversion and Is a Natural Adjuvant of Intestinal Immune Responses. <i>Immunity</i> , 2008, 29, 637-649.	14.3	446
9	Cell-Mediated Immune Response to Human Immunodeficiency Virus (HIV) Type 1 in Seronegative Homosexual Men with Recent Sexual Exposure to HIV-1. <i>Journal of Infectious Diseases</i> , 1992, 165, 1012-1019.	4.0	396
10	Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. <i>Nature Medicine</i> , 2005, 11, 1238-1243.	30.7	366
11	Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGF $\beta$ ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e90353.	2.5	328
12	Strategies for designing and optimizing new generation vaccines. <i>Nature Reviews Immunology</i> , 2001, 1, 209-219.	22.7	319
13	Chapter 8 The Role of NKT Cells in Tumor Immunity. <i>Advances in Cancer Research</i> , 2008, 101, 277-348.	5.0	274
14	Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9458-9463.	7.1	263
15	A nonclassical non-V $\alpha$ 14J $\beta$ 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. <i>Journal of Experimental Medicine</i> , 2005, 202, 1627-1633.	8.5	262
16	Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. <i>Scientific Reports</i> , 2017, 7, 1878.	3.3	260
17	Immunoregulatory T cells in tumor immunity. <i>Current Opinion in Immunology</i> , 2004, 16, 157-162.	5.5	237
18	Transforming Growth Factor $\beta$ Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17. <i>Cancer Research</i> , 2008, 68, 3915-3923.	0.9	233

#	ARTICLE	IF	CITATIONS
19	Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. <i>Nature</i> , 1989, 339, 383-385.	27.8	232
20	Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. <i>Nature Medicine</i> , 2001, 7, 1320-1326.	30.7	231
21	Target Cell Lysis by CTL Granule Exocytosis Is Independent of ICE/Ced-3 Family Proteases. <i>Immunity</i> , 1997, 6, 209-215.	14.3	210
22	An Anti-Transforming Growth Factor $\beta$ Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments. <i>Cancer Research</i> , 2008, 68, 3835-3843.	0.9	203
23	Cytotoxic T cells specific for the circumsporozoite protein of <i>Plasmodium falciparum</i> . <i>Nature</i> , 1988, 334, 258-260.	27.8	201
24	Dendritic Cells in Antitumor Immune Responses. <i>Cellular Immunology</i> , 1996, 170, 111-119.	3.0	199
25	High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL. <i>Journal of Immunology</i> , 2001, 166, 1690-1697.	0.8	196
26	IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. <i>Journal of Experimental Medicine</i> , 2013, 210, 491-502.	8.5	190
27	Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis. <i>Journal of Immunology</i> , 2007, 179, 5126-5136.	0.8	187
28	Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. <i>Journal of Clinical Investigation</i> , 2004, 113, 998-1007.	8.2	182
29	Role of IL-13 in regulation of anti-tumor immunity and tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 79-85.	4.2	181
30	CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy. <i>Cancer Research</i> , 2014, 74, 6771-6783.	0.9	179
31	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. <i>Journal of Clinical Investigation</i> , 2004, 113, 1515-1525.	8.2	175
32	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3392-3397.	7.1	174
33	Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5099-5107.	1.6	167
34	Cellular Immune Responses to Human Papillomavirus (HPV) 16 L1 in Healthy Volunteers Immunized with Recombinant HPV 16 L1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2003, 188, 327-338.	4.0	159
35	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. <i>Nature</i> , 1988, 334, 706-708.	27.8	158
36	Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. <i>Nature Medicine</i> , 2012, 18, 1291-1296.	30.7	156

#	ARTICLE	IF	CITATIONS
37	Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16260-16265.	7.1	155
38	Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. Journal of Clinical Investigation, 2010, 120, 607-616.	8.2	155
39	Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design. Immunological Reviews, 1987, 98, 9-52.	6.0	144
40	Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. International Immunology, 1993, 5, 849-857.	4.0	142
41	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clinical Cancer Research, 2008, 14, 4850-4858.	7.0	142
42	Selective Inhibition of Regulatory T Cells by Targeting the PI3K/Akt Pathway. Cancer Immunology Research, 2014, 2, 1080-1089.	3.4	131
43	Excess $\beta_2$ microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature, 1991, 349, 74-77.	27.8	128
44	IL-15 as a mediator of CD4 <sup>+</sup> help for CD8 <sup>+</sup> T cell longevity and avoidance of TRAIL-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5201-5206.	7.1	128
45	DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 2002, 100, 1153-1159.	1.4	127
46	Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa. Blood, 2006, 107, 3258-3264.	1.4	127
47	Immunobiology of Mucosal HIV Infection and the Basis for Development of a New Generation of Mucosal AIDS Vaccines. Immunity, 2004, 20, 247-253.	14.3	125
48	IL-15/IL-15R $\alpha$ -mediated avidity maturation of memory CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15154-15159.	7.1	123
49	Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. Journal of Immunology, 2003, 170, 2523-2530.	0.8	120
50	NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis. Journal of Immunology, 2008, 180, 3627-3635.	0.8	115
51	Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunology Research, 2016, 4, 354-365.	3.4	114
52	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	1.6	113
53	NKT Cell Networks in the Regulation of Tumor Immunity. Frontiers in Immunology, 2014, 5, 543.	4.8	110
54	Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN- $\beta$ Dependent. Journal of Immunology, 2002, 169, 5796-5804.	0.8	109

#	ARTICLE	IF	CITATIONS
55	Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor- $\beta$ Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2009, 15, 6560-6569.	7.0	109
56	Antigen Processing for Presentation to T Lymphocytes: Function, Mechanisms, and Implications for the T-Cell Repertoire. <i>Immunological Reviews</i> , 1988, 106, 5-31.	6.0	107
57	Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein. <i>Journal of Virology</i> , 1998, 72, 8264-8272.	3.4	105
58	Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor $\beta$ by the monoclonal antibody fresolimumab (GC1008). <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 437-446.	4.2	104
59	Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8 + T-Cell Peptide Epitope of Vaccinia and Variola Viruses. <i>Journal of Virology</i> , 2004, 78, 7052-7060.	3.4	101
60	Immunostimulatory DNA-Based Vaccines Elicit Multifaceted Immune Responses Against HIV at Systemic and Mucosal Sites. <i>Journal of Immunology</i> , 2001, 167, 1584-1591.	0.8	100
61	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. <i>Cancer Research</i> , 2006, 66, 11070-11076.	0.9	98
62	Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. <i>Immunological Reviews</i> , 1999, 170, 151-172.	6.0	94
63	A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques against Simian/Human Immunodeficiency Viral Depletion of Mucosal CD4+ T Cells. <i>Journal of Immunology</i> , 2007, 178, 7211-7221.	0.8	93
64	The Contrasting Roles of NKT Cells in Tumor Immunity. <i>Current Molecular Medicine</i> , 2009, 9, 667-672.	1.3	90
65	Supraoptimal Peptide-Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor $\alpha$ Receptor II-mediated Apoptosis of Cytotoxic T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1998, 188, 1391-1399.	8.5	89
66	A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13020-13025.	7.1	89
67	A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 373-384.	4.2	89
68	Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. <i>International Journal of Cancer</i> , 2005, 114, 80-87.	5.1	88
69	Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9843-9848.	7.1	88
70	Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity. <i>Journal of Immunology</i> , 2003, 171, 5842-5852.	0.8	87
71	Tissue-Specific Roles of NKT Cells in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1838.	4.8	87
72	Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 8022-8028.	0.9	86

#	ARTICLE	IF	CITATIONS
73	Interplay of Cytokines and Adjuvants in the Regulation of Mucosal and Systemic HIV-Specific CTL. <i>Journal of Immunology</i> , 2000, 165, 6454-6462.	0.8	85
74	High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1597603.	12.2	83
75	Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor- $\alpha 2$ . <i>Cancer Research</i> , 2008, 68, 3467-3475.	0.9	81
76	Early Role of CD4 <sup>+</sup> Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas. <i>Journal of Immunology</i> , 2005, 174, 4228-4236.	0.8	80
77	Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines. <i>Current Molecular Medicine</i> , 2003, 3, 285-301.	1.3	75
78	Granulocyte-Macrophage Colony-Stimulating Factor Expressed by Recombinant Respiratory Syncytial Virus Attenuates Viral Replication and Increases the Level of Pulmonary Antigen-Presenting Cells. <i>Journal of Virology</i> , 2001, 75, 12128-12140.	3.4	74
79	Immunodominance in T lymphocyte recognition. <i>Immunology Letters</i> , 1988, 18, 83-92.	2.5	73
80	Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. <i>International Immunology</i> , 2001, 13, 897-908.	4.0	73
81	Blockade of TGF- $\beta 2$ enhances tumor vaccine efficacy mediated by CD8 <sup>+</sup> T cells. <i>International Journal of Cancer</i> , 2010, 126, 1666-1674.	5.1	72
82	High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. <i>Journal of Clinical Investigation</i> , 2001, 108, 1677-1685.	8.2	72
83	Molecular Mechanisms and Biological Significance of CTL Avidity. <i>Current HIV Research</i> , 2003, 1, 287-294.	0.5	71
84	The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 199-213.	4.2	71
85	Blockade of only TGF- $\beta 1$ and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. <i>OncImmunology</i> , 2017, 6, e1308616.	4.6	71
86	An Ia-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. <i>Survey of Immunologic Research</i> , 1983, 2, 223-229.	0.4	71
87	Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 2610-2618.	0.9	70
88	Progress on new vaccine strategies against chronic viral infections. <i>Journal of Clinical Investigation</i> , 2004, 114, 450-462.	8.2	68
89	Impairment of Gag-Specific CD8 <sup>+</sup> T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques. <i>Journal of Virology</i> , 2001, 75, 11483-11495.	3.4	67
90	Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 <sup>+</sup> T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels. <i>Journal of Virology</i> , 2006, 80, 3732-3742.	3.4	67

#	ARTICLE	IF	CITATIONS
91	Minimal requirements for peptide mediated activation of CD8+ CTL. <i>Molecular Immunology</i> , 1994, 31, 1285-1293.	2.2	66
92	Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. <i>International Immunology</i> , 2001, 13, 817-824.	4.0	61
93	KLF13 sustains thymic memory-like CD8+ T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. <i>Journal of Experimental Medicine</i> , 2011, 208, 1093-1103.	8.5	61
94	Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2015, 194, 4215-4221.	0.8	60
95	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. <i>Pathogens</i> , 2021, 10, 138.	2.8	60
96	Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates. <i>Journal of Virology</i> , 2001, 75, 4430-4434.	3.4	59
97	Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity. <i>Cancer Research</i> , 2013, 73, 1514-1523.	0.9	59
98	Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
99	Vaccine-induced myeloid cell population dampens protective immunity to SIV. <i>Journal of Clinical Investigation</i> , 2014, 124, 2538-2549.	8.2	58
100	Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. <i>Journal of Immunology</i> , 2017, 198, 3494-3506.	0.8	57
101	Development of artificial vaccines against HIV using defined epitopes. <i>FASEB Journal</i> , 1991, 5, 2412-2418.	0.5	54
102	FcÎµ receptor-positive cells are a major source of antigen-induced interleukin-4 in spleens of mice infected with <i>Schistosoma mansoni</i> . <i>European Journal of Immunology</i> , 1993, 23, 1910-1916.	2.9	54
103	CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-Î². <i>Cancer Research</i> , 2006, 66, 3869-3875.	0.9	54
104	Multiple Antigen Peptide Vaccines against <i>Plasmodium falciparum</i> Malaria. <i>Infection and Immunity</i> , 2010, 78, 4613-4624.	2.2	53
105	Increased susceptibility of mice infected with <i>Schistosoma mansoni</i> to recombinant vaccinia virus: Association of viral persistence with egg granuloma formation. <i>European Journal of Immunology</i> , 1994, 24, 3050-3056.	2.9	52
106	Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection. <i>Journal of Virology</i> , 2002, 76, 10507-10511.	3.4	52
107	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .	5.0	52
108	A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1679-1683.	4.2	50

#	ARTICLE	IF	CITATIONS
109	Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. <i>European Journal of Immunology</i> , 2008, 38, 1706-1720.	2.9	50
110	Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. <i>Virology</i> , 2008, 381, 106-115.	2.4	50
111	Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 259-272.	1.1	49
112	Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. <i>Cellular Immunology</i> , 1987, 105, 301-316.	3.0	48
113	Epitope Selection and Design of Synthetic Vaccines Molecular Approaches to Enhancing Immunogenicity and Cross-Reactivity of Engineered Vaccines. <i>Annals of the New York Academy of Sciences</i> , 1993, 690, 256-264.	3.8	48
114	Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. <i>European Journal of Immunology</i> , 1991, 21, 1345-1349.	2.9	45
115	HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. <i>Aids</i> , 1999, 13, 2003-2012.	2.2	44
116	Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host. <i>Journal of Immunology</i> , 2006, 177, 6336-6343.	0.8	42
117	Prediction of HIV Peptide Epitopes by a Novel Algorithm. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 593-610.	1.1	41
118	Mouse and human iNKT cell agonist $\beta$ -mannosylceramide reveals a distinct mechanism of tumor immunity. <i>Journal of Clinical Investigation</i> , 2011, 121, 683-694.	8.2	41
119	The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response. <i>Journal of Virology</i> , 2006, 80, 5958-5967.	3.4	39
120	Cancer vaccines: translation from mice to human clinical trials. <i>Current Opinion in Immunology</i> , 2018, 51, 111-122.	5.5	39
121	Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice. <i>Journal of Virology</i> , 2007, 81, 8774-8783.	3.4	38
122	Avidity of CD8 T cells sharpens immunodominance. <i>International Immunology</i> , 2007, 19, 497-507.	4.0	38
123	Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine. <i>Cancer Research</i> , 2008, 68, 1979-1987.	0.9	38
124	Cancer vaccine strategies: translation from mice to human clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1863-1869.	4.2	38
125	Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors. <i>Cancer Research</i> , 2006, 66, 1818-1823.	0.9	37
126	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 685-694.	3.4	37

#	ARTICLE	IF	CITATIONS
127	Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer. <i>Seminars in Oncology</i> , 2012, 39, 348-357.	2.2	36
128	The effect of antigen dose on T cell-targeting vaccine outcome. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 407-411.	3.3	36
129	Structural comparison of a 15 residue peptide from the V3 loop of HIV-1 with an O-glycosylated analogue. <i>FEBS Letters</i> , 1996, 393, 280-286.	2.8	35
130	Oral vaccines. <i>Gut Microbes</i> , 2013, 4, 246-252.	9.8	35
131	Episomal Expression of Truncated Listeriolysin O in LmddA-LLO-E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3 <sup>+</sup> and CD8+ T Cells. <i>Cancer Immunology Research</i> , 2014, 2, 911-922.	3.4	35
132	Sequence features that correlate with MHC restriction. <i>Molecular Immunology</i> , 1994, 31, 1-19.	2.2	34
133	Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. <i>International Journal of Cancer</i> , 2004, 111, 298-302.	5.1	34
134	Hemagglutinin Protein Is a Primary Target of the Measles Virus-Specific HLA-A2-Restricted CD8+T Cell Response during Measles and after Vaccination. <i>Journal of Infectious Diseases</i> , 2007, 195, 1799-1807.	4.0	34
135	Pathogenic Roles of CD14, Galectin-3, and OX40 during Experimental Cerebral Malaria in Mice. <i>PLoS ONE</i> , 2009, 4, e6793.	2.5	34
136	Genetic control of the immune response to staphylococcal nuclease. <i>Seminars in Immunopathology</i> , 1978, 1, 51-83.	4.0	33
137	Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human cytotoxic T lymphocytes. <i>International Immunology</i> , 1996, 8, 641-649.	4.0	33
138	Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen. <i>Journal of Immunology</i> , 2003, 171, 2548-2555.	0.8	33
139	Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaques. <i>Mucosal Immunology</i> , 2018, 11, 1219-1229.	6.0	33
140	Studies on oxidative drug metabolism in the full-term newborn infant. <i>Journal of Pediatrics</i> , 1966, 69, 1139-1149.	1.8	30
141	CORRELATION OF INTRATHYMIC TOLERANCE WITH INTRATHYMIC CHIMERISM IN NEONATALLY TOLERIZED MICE. <i>Transplantation</i> , 1985, 40, 68-72.	1.0	30
142	Mucosal AIDS vaccines: current status and future directions. <i>Expert Review of Vaccines</i> , 2004, 3, S65-S73.	4.4	30
143	A Novel Combination Immunotherapy for Cancer by IL-13R <sup>+</sup> -Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models. <i>Journal of Immunology</i> , 2011, 187, 4935-4946.	0.8	30
144	SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. <i>Frontiers in Immunology</i> , 2021, 12, 658428.	4.8	30

#	ARTICLE	IF	CITATIONS
145	[40] Identification of T-cell epitopes and use in construction of synthetic vaccines. <i>Methods in Enzymology</i> , 1989, 178, 611-634.	1.0	29
146	Binding of Glycoprotein 120 and Peptides from the HIV-1 Envelope by Autoantibodies in Mice with Experimentally Induced Systemic Lupus Erythematosus and in Patients with the Disease. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1071-1077.	1.1	29
147	Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity. <i>Journal of Immunology</i> , 2000, 165, 5703-5712.	0.8	29
148	Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor $\hat{\pm}$ 2 Chain. <i>Cancer Research</i> , 2006, 66, 4434-4442.	0.9	29
149	Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 907-912.	4.2	29
150	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. <i>Journal of Translational Medicine</i> , 2010, 8, 8.	4.4	29
151	Altered Lipid Tumor Environment and Its Potential Effects on NKT Cell Function in Tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2187.	4.8	29
152	Definition of T cell epitopes within the 19â€ƒkDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria. <i>Parasite Immunology</i> , 2002, 20, 263-278.	1.5	28
153	Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. <i>International Journal of Cancer</i> , 2006, 118, 3022-3029.	5.1	28
154	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	8.2	28
155	Plasmodium falciparum: Sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine. <i>Experimental Parasitology</i> , 1987, 64, 64-70.	1.2	27
156	An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL. <i>European Journal of Immunology</i> , 2001, 31, 2951-2959.	2.9	27
157	Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. <i>Microbes and Infection</i> , 2001, 3, 1051-1061.	1.9	27
158	Characterization of Conserved T- and B-Cell Epitopes in Plasmodium falciparum Major Merozoite Surface Protein 1. <i>Infection and Immunity</i> , 2000, 68, 2685-2691.	2.2	26
159	Expression of Interleukin-4 by Recombinant Respiratory Syncytial Virus Is Associated with Accelerated Inflammation and a Nonfunctional Cytotoxic T-Lymphocyte Response following Primary Infection but Not following Challenge with Wild-Type Virus. <i>Journal of Virology</i> , 2005, 79, 9515-9526.	3.4	26
160	Regulation of tumor immunity: the role of NKT cells. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 725-734.	3.1	26
161	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. <i>Journal of Clinical Investigation</i> , 2020, 130, 2789-2799.	8.2	26
162	Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor- $\hat{\pm}$ synergize for IL-12R expression at low antigen dose. <i>International Immunology</i> , 2001, 13, 1433-1442.	4.0	25

#	ARTICLE	IF	CITATIONS
163	Rapid Induction of Apoptosis in CD8+ HIV-1 Envelope-Specific Murine CTLs by Short Exposure to Antigenic Peptide. <i>Journal of Immunology</i> , 2002, 169, 6588-6593.	0.8	25
164	Designing Peptide Vaccines to Broaden Recognition and Enhance Potency. <i>Annals of the New York Academy of Sciences</i> , 1995, 754, 161-168.	3.8	24
165	Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. <i>Clinical Immunology</i> , 2014, 155, 91-107.	3.2	24
166	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmmunology</i> , 2016, 5, e1197459.	4.6	24
167	Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3352-3364.	7.0	24
168	Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006395.	4.7	24
169	IL-15 Expands Unconventional CD8 <sup>+</sup> NK1.1 <sup>+</sup> T Cells but Not V $\beta$ 14 <sup>+</sup> 18 <sup>+</sup> NKT Cells. <i>Journal of Immunology</i> , 2008, 180, 7276-7286.	0.8	22
170	Myoglobin adsorption onto crosslinked polydimethylsiloxane. <i>Journal of Colloid and Interface Science</i> , 1986, 111, 466-474.	9.4	21
171	Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13 <sup>+</sup> 2-Expressing Contralateral Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4678-4686.	7.0	20
172	Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. <i>Clinical Immunology</i> , 2014, 153, 308-322.	3.2	20
173	Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. <i>Journal of Leukocyte Biology</i> , 2016, 99, 475-482.	3.3	20
174	Mechanisms of T cell recognition with application to vaccine design. <i>Molecular Immunology</i> , 1991, 28, 217-223.	2.2	19
175	Repeated determinants within the retinal interphotoreceptor retinoid-binding protein (IRBP): Immunological properties of the repeats of an immunodominant determinant. <i>Cellular Immunology</i> , 1990, 126, 331-342.	3.0	18
176	Molecular Alterations in Pediatric Sarcomas: Potential Targets for Immunotherapy. <i>Sarcoma</i> , 1998, 2, 77-87.	1.3	18
177	TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4 <sup>+</sup> memory T cell loss in SIVmac251-challenged rhesus macaques. <i>Vaccine</i> , 2011, 30, 59-68.	3.8	18
178	Role of conserved regions of class I MHC molecules in the activation of CD8 <sup>+</sup> cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. <i>International Immunology</i> , 1993, 5, 1129-1138.	4.0	17
179	Effect of Zidovudine Postexposure Prophylaxis on the Development of HIV-Specific Cytotoxic T-Lymphocyte Responses in HIV-Exposed Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 428-430.	1.8	17
180	A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. <i>Vaccine</i> , 2012, 30, 4323-4327.	3.8	16

#	ARTICLE	IF	CITATIONS
181	Immune responses to peptides derived from the retinal protein IRBP: Immunopathogenic determinants are not necessarily immunodominant. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, 212-224.	2.0	15
182	Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine. <i>Journal of Immunology</i> , 2006, 176, 3753-3759.	0.8	15
183	Î2-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy. <i>Clinical Cancer Research</i> , 2013, 19, 4404-4411.	7.0	15
184	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. <i>PLoS ONE</i> , 2013, 8, e64365.	2.5	15
185	Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 314.	4.8	15
186	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. <i>Frontiers in Immunology</i> , 2019, 10, 1072.	4.8	15
187	Myeloid Cell-Mediated Trained Innate Immunity in Mucosal AIDS Vaccine Development. <i>Frontiers in Immunology</i> , 2020, 11, 315.	4.8	14
188	The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 638872.	4.8	14
189	How many class II immune response genes? A reappraisal of the evidence. <i>Immunogenetics</i> , 1986, 23, 302-308.	2.4	13
190	Differential T cell homing to colon vs. small intestine is imprinted by local CD11c+ APCs that determine homing receptors. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1381-1388.	3.3	13
191	IL13RÎ2 expression identifies tissue-resident IL-22-producing PLZF <sup>+</sup> innate T cells in the human liver. <i>European Journal of Immunology</i> , 2018, 48, 1329-1335.	2.9	13
192	Possible Therapeutic Vaccine Strategy against Human Immunodeficiency Virus Escape from Reverse Transcriptase Inhibitors Studied in HLA-A2 Transgenic Mice. <i>Journal of Virology</i> , 2006, 80, 10645-10651.	3.4	12
193	IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. <i>Journal of Leukocyte Biology</i> , 2011, 90, 205-214.	3.3	12
194	Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. <i>Sensors</i> , 2018, 18, 2461.	3.8	12
195	Antigenic structures recognized by T cells. <i>Aids</i> , 1988, 2, S95-102.	2.2	11
196	Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. <i>Aids</i> , 2000, 14, 1497-1506.	2.2	11
197	Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. <i>Journal of Immunology</i> , 2018, 200, ji1701523.	0.8	11
198	Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals. <i>Journal of Clinical Immunology</i> , 1991, 11, 143-151.	3.8	10

#	ARTICLE	IF	CITATIONS
199	Tumor-induced CD11b <sup>+</sup> Gr <sup>1</sup> myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. <i>European Journal of Immunology</i> , 2015, 45, 1148-1158.	2.9	10
200	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <i>Seminars in Oncology</i> , 2016, 43, 501-513.	2.2	10
201	Interleukin 21 collaborates with interferon- $\beta$ for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. <i>PLoS Pathogens</i> , 2019, 15, e1007614.	4.7	10
202	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
203	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. <i>PLoS ONE</i> , 2015, 10, e0143001.	2.5	9
204	Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. <i>Oncolimmunology</i> , 2019, 8, e1625687.	4.6	9
205	BepiTBR: T-B reciprocity enhances B cell epitope prediction. <i>IScience</i> , 2022, 25, 103764.	4.1	9
206	Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody. <i>Journal of Immunology</i> , 2001, 167, 699-707.	0.8	8
207	Diversity Outbred Mice Reveal the Quantitative Trait Locus and Regulatory Cells of HER2 Immunity. <i>Journal of Immunology</i> , 2020, 205, 1554-1563.	0.8	8
208	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	2.9	8
209	Role of $\beta$ domain of class I MHC molecules in the activation of high- and low-avidity CD8 <sup>+</sup> CTLs. <i>International Immunology</i> , 2007, 19, 1413-1420.	4.0	7
210	Lack of IL $\beta$ and IL $\alpha$ 15 signaling affects interferon- $\beta$ production by, more than survival of, small intestinal intraepithelial memory CD8 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2011, 41, 3513-3528.	2.9	7
211	Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. <i>Expert Review of Vaccines</i> , 2013, 12, 1115-1118.	4.4	7
212	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
213	Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. <i>Cancer Letters</i> , 2021, 499, 279-289.	7.2	7
214	Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8 <sup>+</sup> cytotoxic T lymphocytes by free antigenic peptide. <i>International Immunology</i> , 2001, 13, 43-51.	4.0	6
215	Balance is a key for happiness. <i>Oncolimmunology</i> , 2013, 2, e24211.	4.6	6
216	Early SIV Dissemination After Intrarectal SIVmac251 Challenge Was Associated With Proliferating Virus-Susceptible Cells in the Colorectum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 353-358.	2.1	6

#	ARTICLE	IF	CITATIONS
217	Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. <i>Oncolimmunology</i> , 2018, 7, e1439305.	4.6	6
218	A simple, high-throughput method of protein and label removal from extracellular vesicle samples. <i>Nanoscale</i> , 2021, 13, 3737-3745.	5.6	6
219	The role of NKT cells in gastrointestinal cancers. <i>Oncolimmunology</i> , 2022, 11, .	4.6	6
220	Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type. <i>Molecular Immunology</i> , 1990, 27, 941-946.	2.2	5
221	Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes. <i>Methods in Microbiology</i> , 2010, 37, 35-66.	0.8	5
222	Structure-Function Implications of the Ability of Monoclonal Antibodies Against Î±-Galactosylceramide-CD1d Complex to Recognize Î²-Mannosylceramide Presentation by CD1d. <i>Frontiers in Immunology</i> , 2019, 10, 2355.	4.8	5
223	Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice*. <i>European Journal of Immunology</i> , 2017, 47, 2059-2069.	2.9	5
224	Cytotoxic T lymphocyte (CTL) adherence assay (CAA): a non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. <i>Journal of Immunological Methods</i> , 1997, 201, 1-10.	1.4	4
225	Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. <i>Cytotherapy</i> , 2018, 20, 728-739.	0.7	4
226	High Sensitivity Protein Gel Electrophoresis Label Compatible with Mass-Spectrometry. <i>Biosensors</i> , 2020, 10, 160.	4.7	4
227	Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3089-3089.	1.6	4
228	Improving Immunotherapy: Revisiting the Immunologist's Little Secret. <i>Science Translational Medicine</i> , 2012, 4, 120fs4.	12.4	3
229	Impaired development of HIV-1 gp160-specific CD8+ cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with <i>Helicobacter pylori</i> infection. <i>European Journal of Immunology</i> , 2001, 31, 516-526.	2.9	2
230	Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay. <i>Journal of Immunological Methods</i> , 2008, 333, 71-78.	1.4	2
231	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	12.6	2
232	Synthetic preparation and immunological evaluation of Î²-mannosylceramide and related N-acyl analogues. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 2739-2746.	2.8	2
233	NKT Cells in Tumor Immunity. , 2016, , 460-469.		2
234	A unidirectional carrier effect. <i>Cellular Immunology</i> , 1985, 92, 226-234.	3.0	1

#	ARTICLE	IF	CITATIONS
235	Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. <i>Methods in Microbiology</i> , 2002, 32, 99-123.	0.8	1
236	Complementary approaches to study NKT cells in cancer. <i>Methods in Enzymology</i> , 2020, 631, 371-389.	1.0	1
237	Selecting stable molecular targets for treatment and prevention of AIDS. <i>Genome Informatics</i> , 2005, 16, 254-61.	0.4	1
238	Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals. <i>Vaccines</i> , 2021, 9, 1484.	4.4	1
239	Thomas Alexander Waldmann. <i>Immunity</i> , 2021, 54, 2671-2672.	14.3	0